<span style="FONT-FAMILY: Arial"> <strong>PD-1通路调控淋巴细胞分化参与自身免疫性疾病发生的研究进展</strong> </span>-《天津医科大学学报》

参考文献/References:

[1]Yao Sheng, Chen Lieping. PD-1 as an immune modulatory receptor[J]. Cancer J, 2014, 20(4): 262

[2]Mckinney E F, Lee J C, Jayne D R, et al. T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection[J]. Nature, 2015, 523(7562): 612

[3]Toomer K H, Chen Zhibin. Autoimmunity as a double agent in tumor killing and cancer promotion[J]. Front Immunol, 2014, 5: 116

[4]Kong Y C, Flynn J C. Opportunistic autoimmune disorders potentiated by Immune-Checkpoint inhibitors Anti-CTLA-4 and Anti-PD-1[J]. Front Immunol, 2014, 5: 206.

[5]Pedoeem A, Azoulay-Alfaguter I, Strazza M, et al. Programmed death-1 pathway in cancer and autoimmunity[J]. Clin Immunol, 2014, 153(1): 145

[6]Riella L V, Paterson A M, Sharpe A H, et al. Role of the PD-1 pathway in the immune response[J]. Am J Transplant, 2012, 12(10): 2575

[7]Murakami N, Riella L V. Co-inhibitory pathways and their importance in immune regulation[J]. Transplantation, 2014, 98(1): 3

[8]Rodríguez-Rodríguez N, Apostolidis S A, Penaloza-Macmaster P, et al. Programmed cell death 1 and Helios distinguish TCR-αβ+ double-negative (CD4-CD8-) T cells that derive from self-reactive CD8 T cells[J]. J Immunol, 2015, 194(9): 4207

[9]Dai Suya, Jia Ru, Zhang Xiao, et al. The PD-1/PD-Ls pathway and autoimmune diseases[J]. Cell Immunol, 2014, 290(1): 72

[10]Pauken K E, Nelson C E, Martinov T, et al. Cutting edge: identification of autoreactive CD4+ and CD8+ T cell subsets resistant to PD-1 pathway blockade[J]. J Immunol, 2015, 194(8): 3551

[11]Pan F, Fan H, Liu Z, et al. T cell signaling targets for enhancing regulatory or effector function[J]. Sci Signal, 2012, 5(235): pe32

[12]Park H J, Kim D H, Lim S H, et al. Insights into the role of follicular helper T cells in autoimmunity[J]. Immune Netw, 2014, 14(1): 21

[13]Wei Y J, Feng J H, Hou Z H, et al. Flow cytometric analysis of circulating follicular helper T (Tfh) and follicular regulatory T (Tfr) populations in human blood[J]. Methods Mol Biol, 2015, 1291: 199

[14]Wang L, Sun X G, Qiu J P, et al. Increased numbers of circulating ICOS? follicular helper T and CD38? plasma cells in patients with newly diagnosed primary biliary cirrhosis[J]. Dig Dis Sci, 2015, 60(2): 405

[15]Kim Y U, Lim H, Jung H E, et al. Regulation of autoimmune germinal center reactions in lupus-prone BXD2 mice by follicular helper T cells[J]. PLoS One, 2015, 10(3): e0120294

[16]Li Y J, Zhang F, Qi Y, et al. Association of circulating follicular helper T cells with disease course of NMO spectrum disorders[J]. J Neuroimmunol, 2015, 278: 239

[17]Khan A R, Hams E, Floudas A, et al. PD-L1hi B cells are critical regulators of humoral immunity[J]. Nat Commun, 2015, 6: 5997

[18]Gianchecchi E, Delfino D V, Fierabracci A. Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity[J]. Autoimmun Rev, 2013, 12(11): 1091

[19]Wu Z X, Miao M, Qiu Y H, et al. Association between polymorphisms in PDCD1 gene and aplastic anemia in Chinese Han population[J]. Leuk Lymphoma, 2013, 54(10): 2251

[20]Fujisawa R, Haseda F, Tsutsumi C, et al. Low programmed cell death-1 (PD-1) expression in peripheral CD4(+) T cells in Japanese patients with autoimmune type 1 diabetes[J]. Clin Exp Immunol, 2015, 180(3): 452

[21]Birtas Atesoglu E, Tarkun P, Demirsoy E T, et al. Soluble programmed death 1 (PD-1) is decreased in patients with immune thrombocytopenia (ITP): potential involvement of PD-1 pathway in ITP immunopathogenesis[J]. Clin Appl Thromb Hemost, 2016, 22(3): 248

[22]Okiyama N, Katz S I. Programmed cell death 1 (PD-1) regulates the effector function of CD8 T cells via PD-L1 expressed on target keratinocytes[J]. J Autoimmun, 2014, 53: 1

[23]Ceeraz S, Hall C, Choy E H, et al. Defective CD8+CD28+ regulatory T cell suppressor function in rheumatoid arthritis is restored by tumour necrosis factor inhibitor therapy[J]. Clin Exp Immunol, 2013, 174(1): 18

[24]Mahmoudi M, Rezaiemanesh Alireza, Salmaninejad A, et al. PDCD1 single nucleotide genes polymorphisms confer susceptibility to juvenile-onset systemic lupus erythematosus[J]. Autoimmunity, 2015, 48(7): 488

[25]Okamura T, Sumitomo S, Morita Kaoru, et al. TGF-β3-expressing CD4+CD25(-)LAG3+ regulatory T cells control humoral immune responses[J]. Nat Commun, 2015, 6: 6329

[26]Wong M, La Cava A, Hahn B H. Blockade of programmed death-1 in young (New Zealand Black x New Zealand White)F1 mice promotes the suppressive capacity of CD4+ regulatory T cells protecting from lupus-like disease[J]. J Immunol, 2013, 190(11): 5402

[27]Cho Y N, Kee S J, Kim T J, et al. Mucosal-associated invariant T cell deficiency in systemic lupus erythematosus[J]. J Immunol, 2014, 193(8): 3891

[28]Iwamoto S, Kido M, Aoki N, et al. TNF-α is essential in the induction of fatal autoimmune hepatitis in mice through upregulation of hepatic CCL20 expression[J]. Clin Immunol, 2013, 146(1): 15

[29]Maruoka R, Aoki N, Kido M, et al. Splenectomy prolongs the effects of corticosteroids in mouse models of autoimmune hepatitis[J]. Gastroenterology, 2013, 145(1): 209

[30]Nishiura H, Iwamoto S, Kido M, et al. Interleukin-21 and tumor necrosis factor-α are critical for the development of autoimmune gastritis in mice[J]. J Gastroenterol Hepatol, 2013, 28(6): 982

[31]Nguyen T L, Makhlouf N T, Anthony B A, et al. In vitro induced regulatory T cells are unique from endogenous regulatory T cells and effective at suppressing late stages of ongoing autoimmunity[J]. PLoS One, 2014, 9(8): e104698

[32]Chen Yongwen, Wu Shengxi, Guo Guoning, et al. Programmed death (PD)-1-deficient mice are extremely sensitive to murine hepatitis virus strain-3 (MHV-3) infection[J]. PLoS Pathog, 2011, 7(7): e1001347

[33]Chyuan I T, Tsai H F, Tzeng H T, et al. Tumor necrosis factor-alpha blockage therapy impairs hepatitis B viral clearance and enhances T-cell exhaustion in a mouse model[J]. Cell Mol Immunol, 2015, 12(3): 317

[34]Gardiner D, Lalezari J, Lawitz E, et al. A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection[J]. PLoS One, 2013, 8(5): e63818

[35]Fuller M J, Callendret B, Zhu Baogong, et al. Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1)[J]. Proc Natl Acad Sci U S A, 2013, 110(37): 15001

[36]Wolchok J D, Kluger H, Callahan M K, et al. Nivolumab plus ipilimumab in advanced melanoma[J]. N Engl J Med, 2013, 369(2): 122

[37]Chen D S, Mellman I. Oncology meets immunology: the cancer-immunity cycle[J]. Immunity, 2013, 39(1): 1

[1]郑忠青,焦国慧,郭丽萍综述,等.PD-1通路调控淋巴细胞分化参与自身免疫性疾病发生的研究进展[J].天津医科大学学报,2016,22(06):541-543.

点击复制

PD-1通路调控淋巴细胞分化参与自身免疫性疾病发生的研究进展 (PDF)

分享到：

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

文章信息/Info

参考文献/References:

相似文献/References:

备注/Memo

常用功能

导航/Navigate

工具/Tools

统计/Statistics